Risankizumab对中重度银屑病患者报告结局的影响:UltIMMa-1和UltIMMa-2随机临床试验
该研究整合UltIMMa-1和UltIMMa-2两项52周3期随机双盲试验,纳入997例中重度斑块状银屑病患者,比较Risankizumab与Ustekinumab及安慰剂在症状、健康相关生活质量及心理健康的患者报告结局。结果显示第16周Risankizumab组达到PSS=0、DLQI=0或1及多个MCID的比例显著高于对照,第52周改善持续。
要点
- Risankizumab在第16周显著提高无银屑病症状(PSS=0)患者比例至30.3%。
- Risankizumab组DLQI=0或1比例达66.2%,优于Ustekinumab和安慰剂。
- 第52周Risankizumab对PSS、DLQI和EQ-5D-5L的改善持续优于Ustekinumab。
核心结论
- Risankizumab较Ustekinumab或安慰剂显著改善中重度银屑病症状、健康相关生活质量和心理困扰。
研究设计与样本
- UltIMMa-1和UltIMMa-2为52周3期随机多中心双盲安慰剂和阳性对照试验,全球139个中心开展。
- 纳入≥18岁中重度慢性斑块状银屑病患者,BSA≥10%、PASI≥12、sPGA≥3,共分析997例。
- 患者按3:1:1随机分配至Risankizumab 150 mg、Ustekinumab(45或90 mg按体重)或安慰剂(16周后转Risankizumab)。
主要发现
- 第16周Risankizumab组PSS=0比例为30.3%(181/598),Ustekinumab组15.1%(30/199),安慰剂组1.0%(2/200),均P<.001。
- 第16周DLQI=0或1比例Risankizumab组66.2%,Ustekinumab组44.7%,安慰剂组6.0%,P<.001。
- 第16周达到DLQI MCID比例Risankizumab组94.5%(516/546),Ustekinumab组85.1%(149/175),安慰剂组35.6%(64/180),均P<.001。
- 第16周达到EQ-5D-5L MCID比例Risankizumab组41.7%(249/597),Ustekinumab组31.5%(62/197,P=.01),安慰剂组19.0%(38/200,P<.001)。
- 第16周HADS焦虑MCID比例Risankizumab组69.1%(381/551),Ustekinumab组57.1%(104/182,P=.004),安慰剂组35.9%(66/184,P<.001);抑郁MCID比例分别为71.1%(354/598)、60.4%(96/159,P=.01)、37.1%(59/159,P<.001)。
关键数值与推荐
- PSS=0定义为无银屑病症状,DLQI=0或1定义为对皮肤相关健康生活质量无影响。
- 第52周Risankizumab对PSS、DLQI和EQ-5D-5L的改善较Ustekinumab持续。
临床怎么用
- Risankizumab可显著改善中重度银屑病患者报告的症状、生活质量及心理困扰,支持其以患者为中心的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Demonstrating the value of therapies from a patient's perspective is increasingly important for patient-centered care. OBJECTIVE: To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe psoriasis. DESIGN, SETTING, AND PARTICIPANTS: The UltIMMa-1 and UltIMMa-2 studies were replicate 52-week phase 3, randomized, multisite, double-blind, placebo-controlled and active comparator-controlled trials conducted in 139 sites (including hospitals, academic medical centers, clinical research units, and private practices) globally in Asia-Pacific, Japan, Europe, and North America. Adults (≥18 years) with moderate to severe chronic plaque psoriasis with body surface area (BSA) involvement of 10% or more, Psoriasis Area Severity Index (PASI) scores of 12 or higher, and static Physician's Global Assessment (sPGA) scores of 3 or higher were included. INTERVENTIONS: In each trial, patients were randomly assigned (3:1:1) to 150 mg of risankizumab, 45 mg or 90 mg of ustekinumab (weight-based per label) for 52 weeks, or matching placebo for 16 weeks followed by risankizumab. MAIN OUTCOMES AND MEASURES: Integrated data from 2 trials were used to compare Psoriasis Symptom Scale (PSS) (total score and item scores for pain, redness, itchiness, and burning), Dermatology Life Quality Index (DLQI), 5-level EuroQoL-5D (EQ-5D-5L), and Hospital Anxiety and Depression Scale (HADS), at baseline, week 16, and week 52. RESULTS: A total of 997 patients with moderate to severe chronic plaque psoriasis were analyzed. Across all arms, the mean age was 47.2 to 47.8 years and 68.3% (136/199 for ustekinumab) to 73.0% (146/200 for placebo) were men. Patients' characteristics and PROs were comparable across all treatment arms at baseline (n = 598, 199, 200 for risankizumab, ustekinumab, and placebo, respectively). At week 16, a significantly greater proportion of patients treated with risankizumab than those treated with ustekinumab or placebo achieved PSS = 0, indicating no psoriasis symptoms (30.3% [181/598], 15.1% [30/199], 1.0% [2/200], both P < .001), and DLQI = 0 or 1 indicating no impact on skin-related HRQL (66.2%, 44.7%, 6.0%, P < .001). Significantly greater proportions of patients treated with risankizumab achieved minimally clinically important difference (MCID) than ustekinumab or placebo for DLQI (94.5% [516/546], 85.1% [149/175], 35.6% [64/180]; both P < .001), EQ-5D-5L (41.7% [249/597] vs 31.5% [62/197], P = .01; vs 19.0% [38/200], P < .001), and HADS (anxiety: 69.1% [381/551] vs 57.1% [104/182], P = .004; vs 35.9% [66/184], P < .001; depression: 71.1% [354/598] vs 60.4% [96/159], P = .01; vs 37.1% [59/159], P < .001). At week 52, improvements in patients treated with risankizumab compared with those treated with ustekinumab were sustained for PSS, DLQI, and EQ-5D-5L. CONCLUSIONS AND RELEVANCE: Risankizumab significantly improved symptoms of moderate to severe psoriasis, improved HRQL, and reduced psychological distress compared with ustekinumab or placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02684370 (UltIMMa-1) and NCT02684357 (UltIMMa-2).
引用
- Augustin M, Lambert J, Zema C, et al. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020. PMID: 33052382. doi:10.1001/jamadermatol.2020.3617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。